The Latest Cardiac and Vascular News
Strategic collaboration leverages AliveCor’s diagnostics and AI capabilities MOUNTAIN VIEW, Calif., Feb. 16, 2021 /PRNewswire/ — AliveCor, the leader in AI-based personal ECG technology and provider of enterprise cardiology solutions, today announced a new collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN), a global science-led biopharmaceutical company, to research new disease management solutions in cardiovascular, renal, and […]
Phase 1 results for ION449 (AZD8233) demonstrate best-in-class potential, showing potent, dose-dependent PCSK9 reductions of >90% with favorable safety profile CARLSBAD, Calif., Nov. 30, 2020 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that the biopharmaceutical company AstraZeneca has initiated a Phase 2b clinical trial of ION449 (AZD8233), an investigational antisense medicine designed to reduce blood cholesterol levels […]
WILMINGTON, Del.–(BUSINESS WIRE)–Nine innovative, community-based organizations with tailored approaches to improve heart health received grants totaling $1,043,303 from the AstraZeneca HealthCare Foundation’s Connections for Cardiovascular HealthSM Next Generation program. This marks the first year of grant funding through the Connections for Cardiovascular HealthSM Next Generation program. The program, which builds on the Foundation’s Connections for Cardiovascular HealthSM program […]
Development of integrated AI digital health solutions to help patients better manage their cardiovascular health OAKLAND, Calif.–(BUSINESS WIRE)–Eko today announced a global collaboration with AstraZeneca to accelerate the development of digital health tools for the earlier screening of cardiovascular diseases, including heart failure. Through the collaboration, AstraZeneca and Eko will explore […]
New BRILINTA indication expands treatment to high-risk coronary patients without a history of stroke or heart attack WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca’s BRILINTA® (ticagrelor) has been approved in the US to reduce the risk of a first heart attack or stroke in high-risk patients with coronary artery disease (CAD), the most common type of […]
FARXIGA is the first SGLT2 inhibitor proven to significantly reduce the risk of cardiovascular death and hospitalization for heart failure WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca’s FARXIGA® (dapagliflozin) has been approved in the US to reduce the risk of cardiovascular (CV) death and hospitalization for heart failure in adults with heart failure (NYHA class II-IV) […]
BRILINTA monotherapy reduced bleeding complications with no increased risk of ischemic events in patients with diabetes undergoing percutaneous coronary intervention Consistent results were also observed in patients undergoing complex percutaneous coronary intervention WILMINGTON, Del.–(BUSINESS WIRE)–Results from two subgroup analyses of the Phase IV independent TWILIGHT trial funded by AstraZeneca showed BRILINTA (ticagrelor) […]
New data showed consistent effect of FARXIGA in patients with heart failure with reduced ejection fraction, regardless of background therapy WILMINGTON, Del.–(BUSINESS WIRE)–New data from a sub-analysis of the landmark Phase III DAPA-HF (Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure) trial showed that AstraZeneca’s FARXIGA (dapagliflozin) reduced the incidence of […]
Heart failure is a global pandemic with an estimated 64.3 million cases worldwide in 2017, costing over US$100B per year Drug developers currently lack effective humanized models for preclinical testing of targeted drug candidates in heart failure with preserved ejection fraction The collaboration aims to provide a unique solution for […]
WILMINGTON, Del.–(BUSINESS WIRE)– AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of FARXIGA (dapagliflozin) to reduce the risk of cardiovascular (CV) death or the worsening of heart failure in adults with heart failure with reduced ejection fraction (HFrEF) or […]
